安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ALK and Lung Cancer - American Lung Association
ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
- Treatment Options for ALK+ - ALK Positive
Treatment Options While our tumors share the ALK fusion gene, no two are identical There are many other differences in the tumor that may need to be considered in therapy planning Once you’re diagnosed with ALK+ lung cancer, your oncologist will determine the stage of your lung cancer and consider other factors for personalizing your treatment
- Targeting ALK Rearrangements in NSCLC: Current State of the Art
ALK signaling is activated in cancer cells primarily through three mechanisms: gene fusions, gene amplification, and activating point mutations (2) ALK rearrangements were first identified in 2007 in NSCLC, where the 3′ region of the ALK gene was fused with the 5′ sequence of the echinoderm microtubule-associated protein-like 4 (EML4) gene
- Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
The findings are the latest from the CROWN study Participants were randomly assigned to receive either lorlatinib or crizotinib as a treatment for advanced lung tumors with ALK gene mutations, a disease called ALK-positive lung cancer
- Lung Cancer Mutations: TP53, KRAS, EGFR, ALK, and More - Healthline
Non-small cell lung cancer is linked to many genetic mutations Discover 19 types and subtypes of lung cancer mutations, testing options, and treatments
- Neladalkib Shows Durable Responses in Heavily Pretreated ALK-Positive . . .
ALK fusions are detected in approximately 1% to 4% of lung cancers, most often in adenocarcinomas Although less common than other genetic alterations, they present a significant treatment challenge for affected patients 3 Neladalkib is a next-generation, brain-penetrant ALK inhibitor developed to address key shortcomings of the current ALK-targeted therapies Its design allows it to stay
- ALK Alterations and Treatment Options for ALK+ NSCLC
Panelists review the discovery of ALK gene fusions and how they have reshaped the treatment landscape for a distinct subset of lung cancer patients They describe how these rearrangements activate
- Personalized approaches to lung cancer treatment: A review of targeted . . .
Globally, lung cancer—more specifically, non-small cell lung cancer (NSCLC)—contributes significantly to the death toll from cancer Recent advances in molecular research have identified key genetic mutations that drive tumor growth, including those in the EGFR, KRAS, ALK, and MET genes, accounting for around 80 % of lung cancers that are categorized as non-small cell lung cancer (NSCLC
|
|
|